CLINICAL_TRIALS
trial_result
· 2017-08-16
Clinical Trial Update: A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma [Phase 2]
Summary
Phase 2 biomarker-enriched study of TH-302 (evofosfamide) in subjects with advanced/metastatic melanoma was terminated; results were posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ImmunoGenesis | Conditions: Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-08-16